For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and ...

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating enough to interfere with daily activities. Despite a multitude of treatment ...

Click Therapeutics' digital therapeutic (DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type in the US for preventing attacks in people with episodic migraine.

Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA.